Facts on Drugs Used in Chemotherapy
Active substance: Teniposide
Manufacturer: Bristol-Myers Squibb
Extract from the prescribing information:
"Severe myelosuppression with resulting infection or bleeding may occur."
"Dose-limiting bone marrow suppression is the most significant toxicity associated with VUMON therapy."
"Children at SJCRH with ALL in remission who received maintenance therapy with VUMON at weekly or twice weekly doses (plus other chemotherapeutic agents), had a relative risk of developing secondary acute nonlymphocytic leukemia (ANLL) approximately 12 times that of patients treated according to other less intensive schedules."
The above has been extracted from the Vumon prescribing information on the Bristol-Myers Squibb webpages.